COVID-19 News

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian. 

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research.

SARS-CoV-2, the virus causing the global COVID-19 pandemic, can infect human pancreatic cells and alter their physiology.

Women who receive COVID-19 mRNA vaccines produced by Pfizer-BioNTech or Moderna while in their third trimester of pregnancy generate a strong immune response and pass protective antibodies through umbilical cord blood to their babies.

With vaccine availability growing in New York City and across the country, attention is increasingly turning to those who are eligible but hesitant about getting the shot

Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.

Last spring, as the COVID-19 pandemic hit New York City with full force, Dr. Daniel MacGowan, a neurologist specializing in neuromuscular disease, was asked to consult in a COVID recovery ward.

As the COVID-19 pandemic enters its second year, scientists are urgently investigating ways to detect signs of the SARS-CoV-2 virus before an outbreak emerges.

Fear of COVID-19 and changes to healthcare delivery during the pandemic may be causing people with substance use disorders to avoid seeking any type of care and thus less likely to get treatment for addiction.

Dr. Virginia Pascual has been awarded a grant supplement from the National Institute of Allergy and Infectious Diseases (NIAID) to lead a multi-institutional effort studying differences in immune responses in children infected with SARS-CoV-2.

Researchers from Weill Cornell Medicine, Cornell University and San Jose State University have identified six free planning models for estimating hospital capacity requirements when COVID-19 cases surge.

Weill Cornell Medicine and NewYork-Presbyterian investigators have built a machine-learning tool that can predict SARS-CoV-2 infection based on age, gender, race and 27 routine laboratory test results.

T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus’s function.

It began as a spark of interest in remote healthcare, gained momentum four years ago with the introduction of a suite of digital health services, then exploded when COVID-19 strained the system, making hospital and doctor visits anything but routine. Today, telemedicine—as a panel of experts at an Oct. 1 Weill Cornell Medicine webinar agreed—is no longer a futuristic idea but an immediate and vital tool for doctors and patients alike.

The amount of SARS-CoV-2 virus, or “viral load,” in cancer patients and in the general inpatient population upon hospital admission may predict their risk of dying of the infection, according to a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

With the need for wide scale COVID-19 testing to allow societies reopen safely, a group from Weill Cornell Medicine and other academic medical centers and research organizations have announced the launch of a global competition for low-cost, high-quality and scalable COVID-19 tests, called the COVID-19 XPRIZE, in a letter published Aug. 20 in Nature Biotechnology.

Ear, nose and throat (ENT) faculty discuss how Weill Cornell Medicine has safely and efficiently reopened outpatient otolaryngology following disruption to practice because of COVID-19.

The COVID-19 pandemic will potentially lead to greater disparities in cancer care and outcomes among Black and Hispanic New Yorker.

Neurological complications ranging from headache, malaise and loss of smell to confusion and disabling strokes have been a disturbing consequence of COVID-19.

Weill Cornell Medicine investigators have received a total of $3.5 million from the Patient-Centered Outcomes Research Institute (PCORI) to study the effectiveness of telehealth services during the COVID-19 pandemic, and to develop models that can aid in clinical decision making in the treatment of the virus.